Report: European Alzheimer's Disease (AD) Therapeutics Markets

European Alzheimer's Disease (AD) Therapeutics Markets

Published by

Frost & Sullivan

Published

2006/08

Content info

Product code

FS44974

Price

From US $ 6500

PDF by E-Mail

Approx. 1-2 business days

Hard Copy/CD-ROM

Approx. 3-4 business days

If you need expedited delivery, please call us.

Abstract

This Frost & Sullivan research service titled European Alzheimer' s Disease (AD) Therapeutics Markets provides a detailed analysis of the AD therapeutics markets in Europe. It includes qualitative aspects such as market challenges, drivers and restraints, as well as forecasts of the overall market, and individual market segments. This study also offers a detailed analysis of existing products in the market, product pipelines of leading companies, and strategic recommendations to market participants.

Related Report

Alzheimer disease - new drugs, markets and companies Drug Delivery in Central Nervous System Diseases - technologies, markets and companies Neuroprotection - Drugs, Markets and Companies Commercial Insight: Anticonvulsants - Non-epilepsy label expansions provide blockbuster potential Commercial Insight: Parkinson's Disease - Japan and Europe to drive total market growth